- Home
- DTIL vs FGEN Comparison
DTIL vs FGEN Comparison
Compare DTIL & FGEN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- DTIL
- FGEN
- Stock Information
- Founded
- DTIL 2006
- FGEN 1993
- Country
- DTIL United States
- FGEN United States
- Employees
- DTIL N/A
- FGEN N/A
- Industry
- DTIL Biotechnology: Pharmaceutical Preparations
- FGEN Biotechnology: Pharmaceutical Preparations
- Sector
- DTIL Health Care
- FGEN Health Care
- Exchange
- DTIL Nasdaq
- FGEN Nasdaq
- Market Cap
- DTIL 55.3M
- FGEN 45.0M
- IPO Year
- DTIL 2019
- FGEN 2014
- Fundamental
- Price
- DTIL $5.39
- FGEN $10.98
- Analyst Decision
- DTIL Strong Buy
- FGEN Strong Buy
- Analyst Count
- DTIL 2
- FGEN 2
- Target Price
- DTIL $47.00
- FGEN $146.50
- AVG Volume (30 Days)
- DTIL 84.4K
- FGEN 29.3K
- Earning Date
- DTIL 11-03-2025
- FGEN 11-11-2025
- Dividend Yield
- DTIL N/A
- FGEN N/A
- EPS Growth
- DTIL N/A
- FGEN N/A
- EPS
- DTIL N/A
- FGEN N/A
- Revenue
- DTIL $1,261,000.00
- FGEN $7,346,000.00
- Revenue This Year
- DTIL N/A
- FGEN N/A
- Revenue Next Year
- DTIL $135.19
- FGEN N/A
- P/E Ratio
- DTIL N/A
- FGEN N/A
- Revenue Growth
- DTIL N/A
- FGEN N/A
- 52 Week Low
- DTIL $3.61
- FGEN $4.50
- 52 Week High
- DTIL $9.20
- FGEN $21.94
- Technical
- Relative Strength Index (RSI)
- DTIL 56.34
- FGEN 43.08
- Support Level
- DTIL $5.26
- FGEN $10.29
- Resistance Level
- DTIL $5.94
- FGEN $11.09
- Average True Range (ATR)
- DTIL 0.22
- FGEN 0.55
- MACD
- DTIL 0.02
- FGEN -0.23
- Stochastic Oscillator
- DTIL 55.35
- FGEN 17.90
About DTIL Precision BioSciences Inc.
Precision BioSciences Inc is a genome editing company dedicated to improving life through its genome editing platform, ARCUS. It leverages ARCUS in the development of its product candidates, which are designed to treat human diseases and provide food and agricultural solutions. The ARCUS is in its relatively small size which potentially allows delivery to a wider range of cells and tissues using viral and non-viral gene delivery methods.
About FGEN FibroGen Inc
FibroGen Inc is a biotechnology company focused on discovering, developing, and commercializing novel therapeutics to treat serious cancer biology and anemia. The company operates in one reportable segment: the development and commercialization of novel therapeutics to treat serious unmet medical needs. The company generates the vast majority of its revenue in Europe, followed by Japan. Virtually all of FibroGen's revenue to date has been generated from its collaboration agreements. FibroGen seeks partners with research, development, and marketing capabilities and other resources that strengthen the company's ability to advance product candidates. Geographically, it operates in United States, Japan, Europe and Others.